Guest Lecturers

 
Roberto Gorni
Roberto Gorni works in the Technical Regulations Area of Cosmetica Italia, The personal care Association. He is expert in cosmetic’s regulatory and he provides advice and support in the technical-productive and law field applied to the manufacturing and marketing of cosmetic products. He is a member of several national and international working groups in the cosmetic technical field, and he is frequently a speaker at major conferences and seminars on cosmetic legislation.
 
Graziano Castaldi
Graziano Castaldi devoted his career to design and develop innovative processes for manufacturing Active Pharmaceutical Ingredients including also Cosmetic Active Ingredient. He covered the responsibility for R&D in important pharmaceutical European companies providing support in the technical-productive and marketing. Since 2008 he is founder and main shareholder of a R&D company, Chemelectiva, providing the services to the main generic pharmaceutical as well as cosmetic companies. He is author of many scientific publications and patents and lecturer at several national and international schools, conferences and seminars.
 
Luisa Fiandra

Luisa Fiandra is Researcher and Aggregate Professor in Cytology and Comparative Anatomy at the Department of Earth and Environmental Sciences, University of Milano Bicocca (UNIMIB), Italy, and she is member of the Research Center POLARIS (Particular Matter and Health Risk) and of the Nanotoxicology Laboratory of UNIMIB.

2020 – Research and Assistan Professor in Clinical Biochemmistry at University of Milano Bicocca. Research activity in Nanomedicine; study of the efficiency of biologically active molecules and nanodrugs against tumours and neurodegenerative diseases on advanced 3D cell sytems.

2018 – Researcher and Assistant Professor in Cytology and Comparative Anatomy at University of Milano Bicocca.

2017 – Lab Manager of NanoBioLab, Department of Biotechnology and Biosciences (BtBs), UNIMIB.

2010 – Senior researcher and scientific coordinator of the project “Development of novel nanostructured materials for the diagnosis of breast cancer, inflammatory bowel disease (IBD) and modulation of antiretroviral therapy (HAART) in HIV” (financed by Regione Lombardia), Nanomedicine Unit of the Department of Biomedical and Clinical Sciences L. “Sacco”, University of Milano (UNIMI)

2003 – PhD in Invertebrate Biology; 1998, M.Sc. in Life Sciences, UNIMI.

From 2010 to 2017, LF coordinated pre-clinical studies mainly devoted to the use of nanotechnology for cancer therapy and diagnosis, and for biological barriers overcoming. From 2018 LF is involved in the safety evaluation of different types of nanoproducts by in vitro and in vivo (Zebrafish) assays. Within the current project PROTECT (EU Program H2020), the main area of interest is the safety of metal oxides nanoparticles  on 3D in vitro skin models according to standardized protocols (OECD, ISO).

LF is author of 31 publications in peer-reviewed journals.

 
Francesca Bernacchi
After a PhD in Cosmetic Science and Technology, in 1999 Francesca Bernacchi was enrolled in Cosmetica Italia, the personal care association. In 2008 she joined the Technical – Regulatory Area, where she is still working, giving technical and scientifical support and to member companies. She is an expert in cosmetic, REACH an CLP regulations, participating in several expert teams and working groups at both national and international level. She is frequently invited as a speaker in meetings and seminars .
 
Francesca Granucci
Francesca Granucci is Full Professor at the University of Milano-Bicocca since 2016 and director of the laboratory of Innate Immunity at INGM, Milan since 2019. She received her PhD in Pharmacology and Toxicology from the University of Milan in 1996. She then performed the Post doc at the Dana Farber Cancer Institute – Boston. From 1998 to 2001 she worked as Research Associate at the CNR in Milan, from 2001 to 2006 she worked as Research Associate at the University of Milano-Bicocca and from 2006 to 2016 she was Associate Professor at the University of Milano-Bicocca. She has pioneered systems biology approaches to study complex dynamic processes, such as host-pathogen interactions and the process of dendritic cell maturation. More recently she focused her research activity on signalling events downstream of Pattern Recognition Receptors within cells of the mammalian innate immune system and she identified some of the key functions played by the NFATc family of transcription factors activated in phagocytes in response to PRR agonists
 
Luca Munaron
Luca Munaron is Full Professor of Physiology in the Department of Life Sciences and Systems Biology (University of Torino, Italy).

He is member of the Italian Society for Cardiovascular Research (SIRC), the Italian Physiological Society (SIF), the Scientific Board for the Doctoral School in Life and Health Sciences (Univ of Torino) and the Interuniversity Research Centre on Epistemology and History of Life Sciences- Res Viva (Univ of Rome).

In 1997 he founded the Laboratory of Cellular and Molecular Angiogenesis, and authored more than 100 papers on international Journals. His main research interest is focused on the cellular mechanisms involved in the physiology and patology of the vascular system. He wrote two books and several book reviews in italian, mainly on Evolutionary Physiology and History and Philosophy of Biology.

He attended tens of national and international Congresses and Meetings as invited speaker and chairman and served as reviewer for high impact international journals and research grants.

Since 2011 he is scientific supervisor for University-Industry agreements.

 
Stefania Recalcati
The major research interest of Stefania Recalcati, Associate Professor – University of Milan, is the molecular regulation of iron metabolism. She is currently very active in studying the different expression of iron proteins in various populations of macrophages, thus contributing to dissect peculiar and specific functional roles of polarized macrophages in various pathological conditions. Her studies provided relevant information to understand the molecular basis of iron retention in macrophages during inflammation, an event involved in the pathogenesis of the anemia of chronic diseases. She also started to study iron metabolism in cancer, producing, for example, strong evidences on its key role in cholangiocarcinoma development and progression.

Less recently she also took part in studies regarding the modifications of iron metabolism under conditions of increased erythropoiesis and pathological conditions, such as oxidative stress and inflammation. In the past she studied and described the abnormal expression of iron-related proteins in hereditary hemochromatosis.

 
Carlo Selmi
Dr. Selmi received his MD in 1998 and his PhD in Internal Medicine in 2002, both from the University of Milan. He was appointed Assistant Professor by the same University for Internal Medicine in 2006 and for Rheumatology since 2011. In 2004 he was awarded the Young Researcher prize by the Italian Society of Internal Medicine and in 2005 the Young Investigator Award by the Aesku-Kipp Foundation. Dr. Selmi was a post-doctoral researcher between august 2001 and december 2004 at the Division of Rheumatology, Allergy, and Clinical Immunology of the University of California, Davis School of Medicine. Since July 2005, he was appointed Assistant Adjunct Professor of Medicine by the same Division at UC Davis.

Carlo Selmi currently leads the Rheumatology and Clinical Immunology Unit at Humanitas research hospital. At Humanitas he leads a young group of physician scientists with wide research and clinical expertise, including periods working at foreign institutions. The team holds dedicated clinics for rheumatoid arthritis, spondiloarthritis, connective tissue disease with dedicated clinics for systemic sclerosis and systemic lupus erythematosus, and is active in articular ultrasound, videocapillaroscopy, arthrocenthesis and intra-articular injections.

He has coauthored over 300 peer-reviewed publications with a Scopus H index of 55 and a total impact factor exceeding 2000. His research track is dedicated to organ-specific and systemic autoimmune and chronic inflammatory diseases, including the clinical epidemiology and pathogenetic mechanisms of autoimmune liver disease, connective tissue disease (particularly systemic sclerosis), and psoriatic arthritis. His work has been funded by the National Institutes of Health, American Liver Foundation, American Scleroderma Foundation, Italian Ministry of Health, Italian Ministry of Foreign Affairs, and the Lilly Research Foundation.

 
Francesco Di Pierro
Francesco Di Pierro is the Scientific Director of Velleja Research a company whose aim is to provide the biopharmaceutical development of products, whether dietary supplements, medical devices, cosmetics or medicines

Thanks to his passion for pharmacological, phytotherapeutic and nutritional sciences, Di Pierro’s interest follows the need for rational ideation and scientific development of new products/preparations for the pharmaceutical, nutraceutical and cosmetic sectors, as well as of medical devices with particular regard to the branch of dietary supplements and phytotherapeutic remedies.

 
Eleonora Bassino
She received her master degree in Sanitary Biology at the University of Turin in 2007. In 2013 she obtained the title of PhD in Experimental Medicine and Therapy (Cardiovascular Physiology) at the University of Turin, Italy.
After the PhD she started her post-doctoral activity in the Cellular and Molecular Angiogenesis Laboratory at the Department of Life Sciences and Systems Biology, Turin, Italy. Her research focuses on the characterization of the paracrine communication between cells that populate dermal/epidermal interface and sub-cutaneous vasculature. In collaboration with pharmaceutical companies she pays her attention on the characterization of the role of natural alternative strategies during skin alteration (i.e. Androgenetic Alopecia) using in vitro co-culture and tri-culture approaches.
 
Alessio Tacchi
Alessio Tacchi, Master degree in Chemistry and Pharmaceutical Technologies in UPO in 2003, is the Head of Process Technology in Procos, an important API manufacturer in the Novara Area. Along his career he has gained excellent experience in the scale-up of industrial chemical processes, besides in their optimization and technology transfer on different productive lines, with more than 25 chemical processes successfully scaled-up and industrialized, for more than 100 different synthetic steps. His experience gave him an excellent knowledge in the plants for the batch production of APIs and pharmaceutical intermediates as well as an excellent experience in plant management, setting-up, modification and improvement.
 
Andrea Cavagnino
Andrea Cavagnino, Study Director at OxiProteomics, PhD in Science of Bioactive Molecules and interested in the molecular mechanisms of aging and aging-associated diseases.

After several years of international research in Italy, UK and France, he joined OxiProteomics in 2015, an innovative technology-driven biotech company in Paris, providing science-based solutions to promote healthy living and healthy aging of human population.

 
Carlo Tremolada
Plastic and maxillofacial surgeon with broad experience and highly innovative approach.

Regenerative medicine has become a major focus after patenting Lipogems technology in 2010 with strong collaborative ties with major world institutions. The focus remains in translational clinical research with thousands of patients treated and followed and teaching courses on Lipogems use worldwide.

  • 1983-1989 School of Medicine and Surgery – University of Milan, Italy Medical degree (October 1989)
    • 1989-1994 Post-graduate school of Plastic and Reconstructive Surgery – University of Parma – Specialization in Plastic Reconstructive and Aesthetic Surgery (July 1994)
    • 1994-1996 Department of Plastic Surgery – Lodi Hospital, Legnano Hospital, Niguarda Hospital Internship and collaboration in research projects and teaching courses
    •1996-2004 Post-graduate school of Maxillo-facial surgery – University of Parma Contract Professor (course: surgical anatomy of the face )
    • Sept 1996-May 2010 Chief of Plastic Surgery sevice, Department of Maxillo-facial Surgery, San Paolo Hospital Reconstructive surgery of acquired and congenital anomalies of the face and body
    • 1999-2003 Post-graduate school of Maxillo-facial surgery Specialization in Maxillo-facial surgery (July 2003)
    • 2005-2010 School of Dentistry – University of Florence
    Contract Professor (course: plastic and reconstructive surgery of the face)
    • Feb 2010-May 2010 Adjunct professor DRI institute – University of Miami
    Research on adipose derived mesenchimal stem cell (DRI federation)
    • May 2010- Consultant Plastic and Maxillo-facial surgeon in different public and private Institutions and universities
  • Head of Istituto image Srl
 
Marisa Gariglio
Marisa Gariglio MD, PhD, is Professor of Medical Microbiology at the Medical School of Novara, University of Piemonte Orientale, Novara-Italy. She received her degree in Biology in 1984 and her Medical degree in 1990 from the University of Turin-Italy, where she also completed her PhD program in Immunology and Virology. After post-doctoral training at the Department of Molecular Biology “Hoffmann La Roche” (Basel-Switzerland) studying transcriptional regulation of interferon-inducible genes, she joined the Novara Medical School in 1996 as Assistant Professor. Since 2001, she is full professor and P.I. of the laboratory of Molecular Virology.  Her laboratory has interests in the pathogenesis, molecular genetics and biochemistry of human papillomaviruses (HPV). Emphasis has been placed on understanding betaHPV-epithelial keratinocyte interactions in naturally occurring patient lesions, such as skin cancer developing in immunosuppressed patients (including organ transplant recipients) and patients suffering from primary immunodeficiency (including Epidermodysplasia verruciformis), and on developing experimental model skin systems (organotypic raft cultures and transgenic mice) that closely reflect these events. Her background is also including the interferon system, particularly the role of the DNA sensor IFI16 in intrinsic antiviral immunity against cytomegalovirus and papillomavirus. At present her h-index is 35.

 

 
Andrea Maltagliati
Andrea MALTAGLIATI is the Market Manager for Personal Care in Roelmi HPC. He is in charge of planning medium-long term strategies by looking at worldwide market trends. Thanks to the acquired know-how in the biofermentation processes, Andrea is also Product Manager for Biotechnology product lines such as PrincipHyal full spectrum hyaluronans. After an initial experience as technical director in an Italian distribution company for cosmetic, he gradually gained experience developing business in other European countries (and worldwide) as marketing manager, export manager and sales manager. Andrea MALTAGLIATI joined Principium Europe in 2012, where he helped build the strong company reputation as supplier of active ingredients, thanks to his technical background and international expertise. Before joining to Roelmi HPC he had an experience as Product Manager for 3 years in a multinational company. Graduated in Chemistry at Milan University, Andrea naturally owns innate effective communication skills and speaks fluent English.

 

 
Mercedes Procopio
Mercedes Procopio received her degree in Chemistry and her specialization in Cosmetic Science and Technologies at the University of Milan. Since 1999 she has been involved in the Regulatory Affairs sector at companies that produce make-up for third parties.  Since 2015 she in Regulatory Affairs Manager at Art Cosmetics. She is president of the Technical Committee of Cosmetica Italia, the Italian personal care association.

 

 
Giorgio Corsico
Giorgio Corsico has been the Director of Value & Access & Policy and Regulatory of Amgen, since 2018. He leads the VA&P and Regulatory Team in Italy both at national and regional level, is member of the European Access Leadership Team and is responsible of the reimbursement strategy at national and regional level.

From 2005 to 2018, we was Director of Regulatory & Compliance of Amgen and European Head of Regulatory Affairs, where he directed the Regulatory activities for Europe. He was Member of the European Senior Regulatory Leadership Team. He was also responsible for communication with regulatory agencies regarding regulatory applications, field alerts, recalls, and inspections to address questions, provide routine updates and promote/develop positive relationships. He was Chairman of the International Digital Committee & Regulatory representative in the Multichannel European Team.

From 1990 to 2005, we was Director of Regulatory Affairs and head of Corporate Regulatory staff. In different Companies he had the possibilities to cover different roles of growing responsibilities link into the definition of world-wide registration strategy for medicinal product, cosmetics and medical devices. Furthermore, he was Regulatory advisor for product under development at a corporate level and special projects (like for example “Wisdom”: an I.T. project aiming to put all the Company on a common net, or a Technical Operations project, working on the rationalisation of the production plants).

 
Sara Bacchiega
After having received a PhD in Organic Chemistry in 2007, she worked at the Technology Transfer Office at Politecnico of Milan managing several aspects of the intellectual property rights in relation with the university research activities (prior art research, freedom to operate analysis, patentability of inventions, licensing and cooperation agreement between university and private companies). During the same period she spent several months at the office Technology and Research Service of Heriot Watt University in Edinburgh and at the Technology Licensing Office at MIT in Boston to cooperate in the exploitation of IP rights. Between 2010 and to 2014 she worked as licensing manager of IP rights at the consultant company Mito Technology srl.

Since 2014 she has joined Procos SpA, a subsidiary of the Japanese company, CBC Co. Ltd Group specialized in the development, scale-up and production of Active Pharmaceutical Ingredients (APIs), as Business Development & IP Expert. Thanks to her expertise she is in charge for the identification and the evaluation of new business opportunities in the field of generic APIs, by analysing the patents landscape related to each business opportunities, the potential project profitability and identifying strategic alliances. Her duties include also the management of the IP rights owned by Procos SpA.

 
Marina Gallarate

Marina Gallarate is Associate Professor at the University of Torino since 2001. She received her PhD in Pharmaceutical Chemistry from the University of Turin and she worked as Research Associate at the University of Torino from 1990 to 2001. She is teacher in the Courses ”Tecnologia, Socioeconomia e Legislazione Farmaceutiche I and II“ in the Combined Bachelor and Master -300 ECTS in Pharmacy and in in the Specialization School in Hospital Pharmacy.

After several-year experience in the cosmetic fields, her recent research is focused on advanced pharmaceutical technology, aimed to the development of nano/micro-systems such as micro/nanoemulsions, liposomes, lipid micro/nanoparticles, nanocomposite hydrogels as possible drug delivery systems for different administration routes.

She is author or co-author of almost 100 peer-reviewed research papers on international journals, some Italian patent and of many congress communications.

 
Elena Peira
Elena Peira holds her degree in Pharmaceutical Chemistry and Technology as well as the title of PhD in Drug Chemistry at the University of Turin. She is currently a researcher and aggregate professor in the Department of Drug Science and Technology, Turin, Italy.

The scientific activity concerns the Pharmaceutical and Cosmetic Technology. The research addresses the development and characterization of colloidal systems such as nanoemulsions, microemulsions, micellar solutions, liposomes, nanoparticles etc. and their application in pharmaceutical and cosmetic formulations.

Currently she studies thermosensitive microemulsions and solid lipid nanoparticle to be proposed for ocular drug delivery.

She is member of the Department of Drug Science and Technology (University of Turin) and from 2008 to 2011 she teached Cosmetic Product Chemistry in the degree course of Herbal Product (Savigliano, CN). From 2011 she teaches Cosmetic Product Chemistry in the degree course of Pharmacy and from 2013 she teaches Pharmaceutical Technology, Socioeconomics and Legislation in the degree course of Pharmacy.

At the present, she is co-author of 44 peer-reviewed publications in international journals.

 

 
Simona Sapino
She obtained her degree in Pharmaceutical Chemistry and Technology and then she received the title of PhD in Pharmaceutical Science at the University of Turin, Italy. After the PhD she started her post-doctoral activity in the laboratory of Pharmaceutical Technology at the Department of Drug Science and Technology, Turin, Italy. Her research focused mainly in the study of colloidal systems for the delivery of drugs and/or functional substances. Object of her study were several vehicles such as emulsions, microemulsions, micellar solutions, liposomes, nanoparticles, cyclodextrins, mesoporous silica, etc. and their application in pharmaceutical and cosmetic formulations. Her background also includes in vitro tests with model systems for assessing the release and effectiveness of drug delivery systems; recently she developed an ocular flow cell as a screening tool for innovative ophthalmic formulations. At the present, she is co-author of 47 peer-reviewed publications in international journals.
 
Gabriele Depta
Gabriele Depta is a makeup fanatic and an innovation hunter. She is Director of Research and Innovation at Intercos spa, leader manufacturer of color cosmetics. List of clients include L’Oréal group, Estée Lauder group, LVMH group, Chanel, Sisley, Kiko, etc.

Born in Germany yet grown in Italy her personality was shaped from the best of the two cultures: precision and passion. She graduated in pharmacy at the University of Milan where she held a research grant for two years after graduating and co-authored 3 publications. She dreamt about becoming a great researcher that could help “save the world”.

Gabriele then found a job at a pharmaceutical company where she worked at the regulatory affairs department in charge of technical dossiers which didn’t fulfill her professional ambitions. Call it destiny, in 1997 she got a job offer at Intercos to join their creative marketing team and decided to change course as she was in love with makeup from age 12 and it was a world she could understand.

Having a background in chemistry, Gabriele quickly got involved more and more with the lab dividing her time between marketing and formulation developing winning products that enriched the company’s portfolio and increase the business.

Surely after a few years she became manager of the applied research lab. Being always curious and in search for innovation she collaborated also with the exploratory research and blue sky labs helping shape and grow what ten years later would be hers. In 2011 Gabriele became R&I Director leading the innovation laboratories in Italy, China, Korea, Brazil and USA. Since 2016 Gabriele is in charge of R&D Make up Global Sr. VP – Corporate Exploratory Research – Applied Research – Regulatory Affairs – Corporate Color Development Intercos SPA.

She is also a lecturer at the Master in Cosmetics offered by the University of Milan, enthusiast horticulturist and loving wife and mom.

 
Marco Erreni
Marco Erreni got his bachelor’s degree in Medical Biotechnology in 2005 and his PhD degree in Experimental Pathology and Neuropathology in 2012. Starting from 2007, he has been working at the IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy, in the field of cancer-related inflammation, with a specific focus on macrophage involvement in tumor progression. During his career, he acquired a strong expertise in the field of imaging, in bright field and wide field microscopy, confocal microscopy and 2-photon microscopy. He applies different imaging technologies (including live cell imaging, TIRF, FRAP, FRET, FLIM and STED) to different in vitro and in vivo models to study biological processes in a variety of research fields, including immunology, oncology, cardiovascular disease and neuroscience. He is also involved in the development of new experimental models for pre-clinical optical in vivo imaging and 2 photon intravital microscopy applications. At the moment, he has a position as staff member in the Unit of Advanced Optical Microscopy
at the IRCCS Humanitas Research Hospital.
 
Alessandra Florio
Alessandra Florio graduated in Foreign Languages and Literatures at the University of Milan and obtained her MA in Literary Translation. After that, she went to Turin and attended a course in Digital and Interactive Storytelling at the Scuola Holden.
She currently works in a healthcare communication agency and collaborates with several publishers. In her spare time, she translates novels, writes children books and participates in archery competitions.
Gianluca M.E. Papeo
Gianluca M.E. Papeo works in the Department of Chemistry at Nerviano Medical Sciences (NMS), a Biotech Company dedicated to the discovery of innovative medicines for cancer treatment. Gianluca started his career with a focus on synthetic methodologies and the synthesis of bioactive natural products in both academic and industrial environment. After a brief experience in the process development laboratories of the firm Indena S.p.A., he joined Pharmacia & Upjohn in 1998 (now NMS) as medicinal chemist. In 2001, Gianluca spent a sabbatical leave as Visiting Scientist at the University of Montréal in Professor Hanessian’s laboratories before being appointed Project Leader and, recently, Group Leader. His area of research aims at finding small molecule inhibitors of the DNA Damage Repair (DDR) machinery of cancer cells. One of these inhibitors recently entered Phase I clinical trial for the treatment of specific tumor phenotypes. Gianluca is currently heading a project (in co-development with a Big Pharma) focused on the discovery of an innovative antitumor agent with an unprecedented mechanism of action, and is involved in a number of early stage drug discovery researches.
Simone Gaeta
Simone Gaeta is a Postdoctoral Researcher at the University of Zurich (UZH) in Natural Products Chemistry. He got his Master of Science in Pharmaceutical chemistry and technology in 2016 at Università del Piemonte Orientale (UPO) and his PhD in Chemistry and Biology (sub-class: Natural Products Chemistry) in 2020 at UPO, under the supervision of prof. Appendino Giovanni. During his studies, he discovered a passion for natural cosmetic formulations that he deepened independently by the academic environment. Combining the love for natural products (as actives and as ingredients), he likes to formulate products to make the most cosmetic and medicinal properties of plants from all over the world. Currently, he is employed at the University of Zurich in the group of Dr Michal Shoshan, working on identification on natural chelating agents for lead from different sources (animals, plants).
Nicola Marini
Passionate on sustainability and specialized in designing new products according to circular economy principles. 10+ years of national and international experience in product development and innovation in different industries (i.e. rigid and flexible ood Packaging, C.A.S.E, Fine Chemical, Cosmetic and Pharma). Currently he is responsible for market development of specialty chemicals and biodegradable polymers in Pharma, Cosmetic, Fine Chemical, Plastic and C.A.S.E. in Novamont. Current activities are mainly localized in the European Area, but he is also managing development projects overseas.
Federica Carlomagno
She is a biologist specialized in biomedical research. After the degree in biology at the University of Milan, she worked in the R&D sector in Principium Europe Srl, a company specialized in the development of functional ingredients for cosmetics and nutraceutics. Currently, she is head of the R&D sector for the development of new ingredients in ROELMI HPC Srl, an Italian company involved in the Health and Personal Care market.
Claudio Pari

Claudio Pari has worked at L’Oréal since 1984, after obtaining his degree in Chemistry with a specialization on Analytic Chemistry at the University of Turin. He spent his entire professional career at L’Oréal until June 2021.

At l’Oréal Italia he was Scientific and Technical Regulatory Director before moving to Paris at l’Oréal France as World Technical-Regulatory Director.

In 2012, he was appointed Vice President Asia Pacific for Security and Regulatory Affairs based in Shanghai.

From 2016 to 2020, he finished his career in Paris as World Director of Regulatory Affairs.

During his professional career, he was vice president of the technical committee of Cosmetica Italia president of the cosmetic group of EUCCC (European Chamber of Commerce of China), member of numerous working groups at Cosmetics Europe and president of the China Task Force.

Currently, he is an independent professor and consultant on different subjects such as Regulatory Cosmetics and Asiatic Culture and Geopolitical affairs. 

 
Yves Geysels
Yves Geysels is Visiting Professor of Clinical Trials at the Faculty of Medicine, Department of Biomedical Sciences and has authored more than 50 publications. Currently he is also Director of Clinical Operations at Bone Therapeutics, a bone cell therapy company, specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases. Yves has a vast experience of more than 20 years in managing clinical trials from an operational point of view, within pharmaceutical companies and Contract Research Organizations (CRO), prior joining the Biotech Industry in 2018. He is founder and honorary president of the Belgian Association of Clinical Research Professionals (ACRP.be) and a honorary fellow at the University of Brussels (VUB).
 
Patricia Lienard
After a PhD in Molecular Biology, she worked in private companies in the field of drug development, in different roles covering all aspects of quality assurance and regulatory requirements. As director of operations in accredited labs, she has lead the development and validation of analytical methods used in ISO17025/CLIA/GLP/GCLP/GMP regulatory contexts. As head of production in a CMO specialized in the production of viral vectors, she has supervised the GMP compliance of activities in a sterile/BL3 environment. As head of a clinical unit, she has managed the conduct of phase one clinical trials. Currently director of operations in a company in charge of the supply chain of clinical trials, she supervises the packaging and labelling of IMP, their storage and distribution, as well as the biobanking of human samples.
 
Laure Delbecque
Laure Delbecque holds a PhD in psychological sciences, as well as a Master’s degree in neuropsychology and cognitive psychology awarded by the Université Libre de Bruxelles, Belgium. She is currently Research Scientist at Eli Lilly in the Patient-Focused Outcomes center of expertise. Before joining Lilly, Laure held positions as expert in patient-reorted outcomes (PRO), (e)PRO researcher, Data Management Specialist, and Publication Manager in major consultancy companies. She was also a teaching assistant for statistics applied to human sciences at the Université Libre de Bruxelles and is currently visiting professor at the University of Namur, Belgium, for the Clinical Project Management and Introduction to PRO courses.
 
François Mullier
Head of hematology-hemostasis laboratory of CHU UCL Namur, Yvoir, Belgium. Professor at the Université catholique de Louvain and the Université de Namur. Associate editor of Thrombosis Journal. Member of the Groupe d’Intérêt en Hémostase Périopératoire (GIHP). Founder member and coordinator of the Namur Thrombosis and Hemostasis Center (NTHC). Main topics of research: direct oral anticoagulants, heparin-induced thrombocytopenia, extracellular vesicles.
 
Fabienne George
She obtained her degree in Veterinary medicine at the University of Liege in 1999. In 2008 she received the title of PhD in biological sciences at the University of Louvain la Neuve. Her research focuses on cryopreservation of in vitro bovine embryos. In 2009, with Prof Carlos Graux, she developed a biobank structure in CHU UCL Namur- Godinne site.  The main objective of this structure is to promote clinical and scientific research, especially translational research. She assumes the coordinator function of the biobank.
Isabelle Brenes
Isabelle Brenes is currently Project Manager at Bristol-Myers Squibb via Syneos Health and a visiting lecturer at UNamur. After obtaining a Master in Chemistry, she started her career working as an academic researcher in the field of inflammatory disease. Following this experience, she moved to the clinical research industry and has endorsed various roles within clinical operations in Belgium. Working on a broad diversity of therapeutic domains, for various sponsors and CROs, she has more than 12 years of experience in managing trials and supporting clinical sites and pharmaceutical companies to conduct clinical studies in compliance with Good Clinical Practice and local regulation. On top of her clinical trial expertise, Isabelle is also very interested in developing new Business opportunities and has recently obtained a Master in Executive Management at Solvay Brussels School.

María Pellín Amorós
María is a Pharmacist with a Bioengineering Master (Toxicology and Pharmacology specialization). She has ten years of experience in Quality Assurance, ISO and GMP for the Cosmetic, Pharmaceutical, Medical Devices and Food Industry. She is also an expert in International Regulatory Affairs in the field of dietary supplements, cosmetics and medical devices and Lecturer at Miguel Hernández University (Pharmacy degree). She has also experience as an internal auditor of ISO 9001, ISO 14001, ISO 13485, ISO22716 and cGMP for dietary supplements following 21CFR part 111 (FDA).
Maria Jose Lopez
Maria Jose Lopez is the Marketing and Business Developer of AntalGenics. She has pursued studies in Marketing and in Science. In fact, she has a Bachelor degree in Biology, a BSc in Biochemistry, and a PhD in Neuroscience. After spending 10 years doing research along different positions in Europe, she moved back to Spain and studied Marketing and Sales Management.
Nuria Caturla Cernuda
Dra Nuria Caturla Cernuda has a degree in Biology and a Ph.D. in Biochemistry from the Miguel Hernández University in Elche. She is currently responsible for the New Skin Care Product Development Department at Monteloeder, where she has been working since 2006. With more than 14 years of experience studying the biological activity of phytochemicals, she is an experienced researcher in the management of R&D projects on functional healthy ingredients.
Verónica Rivero
Verónica Rivero is Project leader in Antlagenics SL. She is bachelor on Chemistry, postgraduate on Biochemistry Sciences, Master of Bioengineering (Specialization in Applied Toxicology and Pharmacology) and PhD in Cellular and Molecular Biology (2017) for Miguel Hernandez University (UMH). She started with toxicological research in endocrine disruptors in the Applied Biology department of UMH and during a stay in the Environmental Medicine Institute in Karolinska Institutet in Stockholm (2010-2011). After, she worked as a researcher in R&D projects in Molecular and Cellular Biology Institute (IBMC) of UMH, now known as IDiBE, in collaboration with the company Lipotec-Diverdrugs (2011-2012), acquiring an extensive experience in toxic and pharmacogenomic and high throughput screenings for the development of new active compounds in cosmetic and derma-pharma field. She continued her scientific experience doing her doctoral thesis based on the setting up of a new patch clamp automatic technique for high-throughput screening of libraries and drug discovery (2012-2017) funding by Dravet Syndrome Foundation (Spain Delegation). During the manuscript writing, she began to work as project leader in Antalgenics S.L, managing the identification of new targets and techniques for in vitro drug discovery and validation and characterization of candidates for using in sensorial neurobiology.
Galia Benhamu
She received her Pharmacy degree at the Complutense University of Madrid. She is specialized in toxicology and is a member of the Spanish Association of Toxicologists.

Since her graduation, she has worked in different areas of the Personal Care products industry. She is specialized in Cosmetic Products Regulatory Affairs and works as a Safety Assessor for Cosmetic Products for several companies in the European Union.

She has participated in developing several regulatory strategies that have successfully ended with the registration of an innovative substances or products.

She provides Regulatory support and science-based solutions to international R&D and Personal Care companies as a Toxicologist and Regulatory affairs expert.

She has collaborated as well with different institutions as a lecturer on these matters in post graduate courses and writing legal articles in informational publications for the cosmetic industry.

María Matabuena de Yzaguirre
María Matabuena de Yzaguirre is Operations Director of Invitrotecnia S. L., a biotechnology company dedicated to the development of in vitro tools and protocols.

She graduated in Biological Sciences, completed her PhD in Cellular Biology and Genetics and was a professor and researcher at the Autonoma University of Madrid, participating in both national and international research projects, funded by the Carlos III Health Institute, the Ministry of Science and Technology, the European Regional Development Fund and the European Commission, among others, which led to various publications in specialized journals.

In 2010, she was part of the teaching and research staff of the University of Alcalá de Henares, in the Department of Plant Biology, where he carried out the Scientific Direction of a research project for the development of new products with regenerating properties.

In 2014, she consolidated her professional career in the business world as Laboratory Director and R&D of Invitrotecnia S. L. In 2018, she constitutes ILICE EFFITECH, a Spin-off of the Miguel Hernández University, dedicated to the development and commercialization of Strategic Bioactive Ingredients. He currently coordinates the INVIEW-LABS specialized R&D laboratory platform for the development and evaluation of the efficacy and safety of products for human use.

She has participated as a trainer in all editions of the Course of Experts in Evaluation of Cosmetic Products organized by STANPA and San Pablo CEU, and for a few years, she has been part of the teaching staff of the Master’s Degree in Cosmetics and Dermopharmacy at CESIF.

Lucia Gregorio
Lucia Gregorio, PhD in Molecular Biology at Universidad Miguel Hernández (Elche). She did a postdoc at McGill University (Montreal) funded by L’Orèal-USA. Afterwards, she crossed to industry as Project Manager in AntalGenics, Biotech company of R&D in cosmetic and pharma. During the last 4 years, she has evolved to Customized R&D Manager, participating in writing innovative proposal, looking for novel know-how and communication with clients giving them support and scientific advisory.
Marta García Escolano
Marta García Escolano graduated in Biotechnology at the Polytechnic University of Valencia and carried out her Diploma Thesis at the Albert-Ludwigs University of Freiburg (Germany) on the study of early diagnostic markers in pancreatic cancer.

After finishing a Master in Biomedicine at the University of Alicante, she worked as a researcher at the Neuroscience Institute of Alicante. During her PhD, she studied the involvement of four genes in the initiation and progression of breast cancer at the University General Hospital of Alicante. In 2018, she moved to New York to collaborate in the characterization of a new molecule with antitumor activity at the Memorial Sloan Kettering Cancer Center. In 2019 she obtained her PhD in Experimental Science and Biomedicine and in early 2020 she moved towards Cosmetic Industry joining Prospera Biotech. Currently, as Project Manager, she is working to take to the market the last advances in skin neurosensory research.

Philipp Tsolakis
Philipp Tsolakis is the CEO of the spin-off company AntalGenics, S.L., in Elche. He has been working in science management and administration for 16 years in different countries: Austria, Portugal and Spain.

Philipp holds a Master of Business Administration (MBA) Degree from the Middlesex University London (U.K.). He also studied Management and Economics at the University of Innsbruck (Austria).

Last modified: October 28, 2021

Post Views: 13,106